MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.

Zhitongcaijing · 1d ago
MSD: The TROFUSE-015 trial evaluating SACITUZUMAB TIRUMOTECAN reached the main end point, improving overall survival by one-third.